Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer

Davide Mauri; Nikolaos P. Polyzos; Georgia Salanti; Nicholas Pavlidis; John P A Ioannidis

doi:10.1093/jnci/djn414

Abstract

1 min read

Stepwise improvements in efficacy of chemotherapy and targeted treatments cumulatively have achieved major improvements in the survival of patients with advanced breast cancer. Many options that can be used in first and subsequent lines of therapy have comparable efficacy profiles.

Related publications

Article2006

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

Maria Kyrgiou, Georgia Salanti, Nicholas Pavlidis, Evangelos Paraskevaidis, John P A Ioannidis

Article1998

Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer.

George Fountzilas, A. Athanassiades, Vaios Papadimitriou, Meletios A Dimopoulos, D. Bafaloukos, Gerasimos Aravantinos, C. Nicolaides, Haralabos P. Kalofonos, Pavlos Papakostas, Nikolaos I. Xiros, Esma Razi

Article2006

Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis

Davide Mauri, Nicholas Pavlidis, Nikolaos P. Polyzos, John P A Ioannidis

Article2001

Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer

Evangelia Razis, Meletios A Dimopoulos, D. Bafaloukos, Christos Papadimitriou, Anna Kalogera‐Fountzila, Haralabos P. Kalofonos, Evangelos Briassoulis, Epaminontas Samantas, Antonios Keramopoulos, Nicholas Pavlidis, P. Kosmidis, George Fountzilas

Article2016

Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer

Elisa Elena Baracco, Federico Pietrocola, Aitziber Buqué, Norma Bloy, Laura Senovilla, Laurence Zitvogel, Erika Vacchelli, Guido Guido Kroemer